Explore the Agenda
8:00 am Check-In & Coffee
Grab a coffee and build upon relationships from day one in the hour before the conference begins
8:50 am Chair’s Opening Remarks
Measuring What Matters: Redefining Biomarkers & Endpoints for Treg Therapeutic Success
9:00 am Panel Discussion: Unearthing Strategies to Define & Measure Treg Modulation
- Defining effective Treg modulation to develop a standardized measurement of efficacy beyond the number of Tregs
- Evaluating genomic screening, cytokine measurement, Treg biology and tissue samples to identify the most effective strategy to measure Treg efficacy
- Highlighting the endpoint and efficacy criteria required for regulatory approval
- Discussing the translatability of preclinical mouse model biomarkers to patients
10:00 am NEW DATA: Leveraging Big Data to Discover Novel Treg Biomarkers
- Exploring the methodology to apply big data strategies to uncover and validate biomarkers that track Treg expansion, stability, and therapeutic response
- Leveraging successes in big data analyses in the context of T-cell therapies for cancer to demonstrate the possibilities in Treg research
- Explore lineage tracing and spatial omics to identify Treg markers beyond traditional analyses
- Overview of methodology, sample types, and assays for correlative studies in Treg cell therapy trials
10:30 am Morning Break & Networking
Redefining Autoimmune Skin Disease Treatment with Treg Innovations in Atopic Dermatitis & Vitiligo
11:30 am NEW DATA: Keynote Presentation: Unraveling Targeted Treg Therapies for Autoimmune Diseases in the skin
- Understanding the pathogenesis of autoimmune diseases in the skin to identify and target disease-driving mechanisms with Treg therapies
- Highlighting groundbreaking Trex Biology data
12:00 pm NEW DATA: Driving Durable Relief in Atopic Dermatitis with Nektar’s REZPEG IL-2 Platform
- Showcasing the unique mechanism of Nektar’s REZPEG IL-2 platform and why it is effective in modulating immune balance
- Highlighting long-term maintenance data from the REZOLVE-AD study to demonstrate sustained efficacy and patient benefit
- Exploring how REZPEG can redefine therapeutic expectations for chronic atopic dermatitis management
12:30 pm Lunch Break & Networking
Unlocking CNS Access & Precision Treg Modulation to Transform Neurodegenerative Disease Therapy
1:30 pm Innovating Treg Modulation in Neurodegeneration: A Clinical-Stage Perspective
- Uncovering Longevity Biotech’s Precision Neuroscience Platform and approach to define patient population
- Exploring Longevity Biotech’s immunomodulation technology and to combat neurodegenerative disease
- Providing a clinical update on Longevity Biotech’s therapy
Defining Clinical Success in Treg Therapies from Indication & Patient Selection to Patient Outcomes
2:00 pm Balancing Treg Biology, Profitability & Patient Needs to Drive Smart Indication Selection
- Highlighting the key considerations guide indication selection for Treg therapies
- Exploring the success of antigen specific Treg trafficking to key disease areas to effectively evaluate treatment efficacy and guide indication selection
- Assessing opportunities for leveraging Treg bystander effects to enhance immune modulation across multiple conditions
- Considering how preclinical model availability influences indication strategies, from narrow focus to broader applications
2:30 pm Advancing Non-Cell Therapy Innovations to Combat Autoimmune & Inflammatory Diseases
- Highlighting apoptosis driven immune tolerance key signaling pathways
- Discussing supporting preclinical and mechanistic studies that inform trial design
- Reviewing clinical trial data in celiac disease and primary biliary cholangit